We were not looking for this problem. We found it the way most families do. By living through it.
Shortly after our daughter Lily turned one, Katherine was diagnosed with de novo metastatic triple-negative breast cancer. Katherine approached her diagnosis with precision, discipline, and an unwillingness to lower the standard. She leaned in, focused on treatment, and continued showing up for her family.
Along the way, we discovered something that should not be true: the years immediately following childbirth, one of life’s most meaningful moments, are also among the most dangerous for breast cancer outcomes. And medicine has not caught up.
The biology is actionable. Postpartum involution, the biological process following weaning, creates a measurable, time-limited window with multiple actionable pathways. This is not vague cancer biology. It is a specific physiological window with known mechanisms, preclinical evidence, and early-stage human trials already underway.
The field is not saturated. A small number of focused researchers are doing meaningful work with limited resources. One well-resourced cohort, one linked data system, one biospecimen bank change the research surface area for everyone who comes after. This is exactly where focused philanthropic capital has asymmetric impact.
Progress is not constrained by ideas. It is constrained by infrastructure and focus. We are here to provide both.